Success and problems of long-term levodopa therapy in Parkinson's disease.
about
Preservation of function in Parkinson's disease: what's learning got to do with it?Stem cell-based approach for the treatment of Parkinson's diseaseExpanding frontiers in weight-control research explored by young investigatorsProspects for new restorative and neuroprotective treatments in Parkinson's diseaseBrasofensine treatment for Parkinson's disease in combination with levodopa/carbidopaGDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation.Age influences magnitude but not duration of response to levodopaRAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.Repair of the damaged brain. The Alfred Meyer Memorial Lecture 1998.Asymmetrical lateral ventricular enlargement in Parkinson's disease.Modulation of habit formation by levodopa in Parkinson's disease.Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.Development of allosteric modulators of GPCRs for treatment of CNS disordersClinical spectrum of levodopa-induced complications.Neuroprotection for Parkinson's disease: a new approach for a new millennium.Psychometric Properties of Activity, Self-Efficacy, and Quality-of-Life Measures in Individuals with Parkinson Disease.Gene therapy for Parkinson's disease.Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core.Do neurologists in Germany adhere to the national Parkinson's disease guideline?The functional role of mesotelencephalic dopamine systems.Cognitive outcome after unilateral pallidal stimulation in Parkinson's diseaseThe catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's diseasePolymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.A novel insulinotropic mechanism of whole grain-derived γ-oryzanol via the suppression of local dopamine D2 receptor signalling in mouse isletClinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons.Cognitive functioning after pallidotomy for refractory Parkinson's disease.Interaction of pergolide with central dopaminergic receptorsPeriodontal health and caries prevalence evaluation in patients affected by Parkinson's diseaseAccuracy in the clinical diagnosis of parkinsonian syndromes.Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's diseaseLong-term treatment of Parkinson's disease with bromocriptineNomifensine: effect in Parkinsonian patients not receiving levodopaThe use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsyLarge animal models of neurological disorders for gene therapy.Targeting the progression of Parkinson's disease.A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.
P2860
Q26853387-27DED6D5-D46C-464D-82DB-C372BEDED6B5Q27004330-FC8CE68E-AB5D-4B51-83FB-63B102A3C19BQ28077983-C2D267D2-4B95-4633-8DA7-52E316CB5BC9Q28138668-08686E93-1DA2-4D09-B595-8744BCC813BEQ28201762-C11D20D5-00EC-4D19-9054-CF801E359955Q31900813-098061DE-B454-4C34-B634-B3740DF42E57Q32134305-ACE3DE8C-2376-446B-BDFB-92E0DE268DFBQ33590439-2BE23EA0-D85B-4C7F-BAE2-2E9A4C942DD5Q33607305-4349DE8E-22DF-4E49-83D0-2261ACE091E5Q33628439-6169A0A2-3CF5-4ADC-A7F4-2B75A7254487Q33774931-18A76C1E-E75E-4009-968B-274FD18D8720Q34012649-E584EF4E-2B3D-477F-91DB-07F91B2DE03AQ34081731-E182366E-1E03-4249-8869-1F26142B9A3AQ34116613-4B6CB86E-1778-438E-B482-7056309ED810Q34373958-8AEFEAA5-8476-4D13-86A3-CACE545223F4Q34452721-46311D0F-8A56-454D-AEB4-69E7DB54D31BQ34481778-ED622AD9-BBD5-4505-9A40-5EA3718C9E67Q34506349-B05203B9-F73A-4052-8791-2197040A8CA3Q34534274-99A39133-95BC-445C-86B8-A5F199B7F0FAQ34785967-43F7D732-FB62-4EDD-9DC1-BEFAAF303FF3Q34879044-9A1CD40A-DE56-49AD-A1D4-350CB66D7E0FQ35273641-522D4CC4-8AD3-4B26-A622-CAD04A2D5EE7Q35450152-056FA140-6930-4A9B-B52E-AC47F221A22DQ35456745-D7CFDE4B-C666-4AE2-9F27-FA5AB9F8045FQ35821201-DFC33F5B-CBD7-4173-B70C-8B9A8E3530E8Q36036244-E6D0EDD3-D10F-42DD-B0D6-3CE06747FFC7Q36107140-2A380E2F-68C1-439D-91BF-54F488B7F224Q36169973-BF03BF61-85FD-4A2A-BF57-8318314BEDABQ36318559-99EFB32A-D31C-4703-9A91-96DD05542D33Q36395455-345E1281-A97D-4C01-8847-E130F7AE9F52Q36516071-0DE5A72F-CEAB-47FD-AAA3-76537C82CA71Q36721985-7FFDDDC7-2275-47D9-8AE6-D06F8FCDCF35Q36750148-56E4F4D7-67D6-4BAC-91F4-BE4AACEF936AQ36947508-DF4F5DC7-4FCE-4481-A58A-CD3D40CC89E6Q36991587-4106F160-271F-49AE-97D7-2FECCDADBBD0Q37009076-45BF0DFC-4C96-45EA-8BD1-E9D9CAFEDC9EQ37019938-FD9D95B1-54B0-4ADE-A6C6-8E42DD713EFAQ37265519-58BC0A16-81D8-45B3-92B1-2CA5E73896F9Q37299619-D8598F6D-AC9B-4F17-AAC9-9AF98F519B93Q37300994-A48EFC71-7F70-4F8A-8A2C-7620DCA157E5
P2860
Success and problems of long-term levodopa therapy in Parkinson's disease.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh
1977年學術文章
@zh-hant
name
Success and problems of long-term levodopa therapy in Parkinson's disease.
@en
Success and problems of long-term levodopa therapy in Parkinson's disease.
@nl
type
label
Success and problems of long-term levodopa therapy in Parkinson's disease.
@en
Success and problems of long-term levodopa therapy in Parkinson's disease.
@nl
prefLabel
Success and problems of long-term levodopa therapy in Parkinson's disease.
@en
Success and problems of long-term levodopa therapy in Parkinson's disease.
@nl
P1433
P1476
Success and problems of long-term levodopa therapy in Parkinson's disease.
@en
P2093
J D Parkes
P304
P356
10.1016/S0140-6736(77)91146-1
P407
P577
1977-02-01T00:00:00Z